Toxicological screening
- PMID: 21772764
- PMCID: PMC3127354
- DOI: 10.4103/0976-500X.81895
Toxicological screening
Abstract
Toxicity testing of new compounds is essential for drug development process. The preclinical toxicity testing on various biological systems reveals the species-, organ- and dose- specific toxic effects of an investigational product. The toxicity of substances can be observed by (a) studying the accidental exposures to a substance (b) in vitro studies using cells/ cell lines (c) in vivo exposure on experimental animals. This review mainly focuses on the various experimental animal models and methods used for toxicity testing of substances. The pre-clinical toxicity testing helps to calculate "No Observed Adverse Effect Level" which is needed to initiate the clinical evaluation of investigational products.
Keywords: No Observed Adverse Effect Level; Toxicity; rodents.
Conflict of interest statement
References
-
- Setzer RW, Kimmel CA. Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances. Pure Appl Chem. 2003;75:2151–8.
-
- Gregory Cope W. Exposure classes, toxicants in air, water, soil, domestic and occupational settings. In: Hodgson E, editor. A textbook of modern toxicology. 3rd ed. New Jersey: John Wiley and Sons, Inc; 2004.
-
- Schedule Y. [Last accessed on 2010 Jan 02]. Available from: http://cdsco.nic.in/html/schedule-y%20%28amended%20version-2005%29%20ori...
-
- Stallard N, Whitehead A. Reducing animal numbers in the fixed-dose procedure. Hum Exp Toxicol. 1995;14:315–23. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources